Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02084628
Other study ID # 16078
Secondary ID 2012-000952-32
Status Terminated
Phase Phase 3
First received February 6, 2014
Last updated October 19, 2015
Start date February 2015
Est. completion date August 2015

Study information

Verified date October 2015
Source Bayer
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is an open-label, multi-center study involving babies 0-2 months of age who have liver problems (pathology) and need to have their liver and possibly, the bile ducts imaged using magnetic resonance imaging and injection of a contrast agent (dye). This agent is called Eovist. It has been marketed since 2004 and used in many countries all over the world.

The baby will have blood tests before and after the imaging is done to make sure that there are no unexpected findings before and after the imaging. Also 3 blood samples up to 8 hours after the injection will be obtained in order to measure how much of the dye is in the blood. The baby will have an intravenous line which can be used for the blood samples and will not need to be stick for the blood samples. Several radiologists will evaluate the images. The family doctor will be contacted to find out what was the diagnosis and treatment after the results of the MRI were known. Six months after the study, the parent(s)/legal guardian(s) will be contacted to make sure the that baby did not have any problems, especially with the skin, joints and eyes.


Description:

In order to minimize bias in assessment of the images, blinded reading of the MR images will be performed by 2 blinded readers. The blinded readers will be independent board-certified pediatric radiologists who have no knowledge about the subjects and are not affiliated with any of the clinical sites.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date August 2015
Est. primary completion date August 2015
Accepts healthy volunteers No
Gender Both
Age group N/A to 2 Months
Eligibility Inclusion Criteria:

- Age 0-2 months (must be gestational age 37 to 41 weeks)

- Scheduled to undergo routine contrast-enhanced liver MRI

- Able to comly with the study procedures

Exclusion Criteria:

- Scheduled for any intervention (except lumbar puncture and bone marrow aspiration) during the study period

- If receiving chemotherapy, may have a change in treatment during the study period

- Contraindication for MRI

- Renal insufficiency (estimated glomerular filtration rate < 80% of age-adjusted normal mean value using the Schwartz formula)

- Acute renal failure

- Clinically relevant abnormal laboratory parameter, ie, greater than 3 times the upper limit of the normal range, in particular, liver enzymes and renal function. (Note: if elevations in liver enzyme levels are consistent with the underlying hepatobiliary disease, then the subject may be enrolled.)

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Drug:
Gadoxetate disodium (Eovist/Primovist, BAY 86-4873)
One-time intravenous bolus injection of the study drug 0.1 mL/kg body weight (0.025 mmol/kg BW), administered at a flow rate of 1-2 mL/second
Sodium chloride solution
Followed by a flush of at least 5 mL saline (sodium chloride 0.9% solution), administered at a flow rate of 1-2 mL/second

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Bayer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with additional diagnostic information from combined (pre-contrast and post-contrast) compared with pre-contrast images Number of participants with better: delineation of the border of the lesion, definition of the internal morphology of the lesion, characterization of the lesion, definition of the location of the lesion, assessment of the communication of the lesion with respect to the biliary system and other, specify Up to 1 year after injection No
Primary Number of participants with adverse events as a measure of safety and tolerability Up to 24 hours after injection Yes
Primary Number of participants with serious adverse events as a measure of safety and tolerability Up to 6 months after injection Yes
Secondary Number of lesions detected for the pre-contrast images Up to 1 year after injection No
Secondary Number of lesions detected for the combined images Up to 1 year after injection No
Secondary Number of participants with contrast enhancement of the biliary system for the combined images If relevant to the subject Up to 1 year after injection No
Secondary Contrast enhancement of the biliary system for the combined images assessed by yes or no question This is only assessed if it is relevant to the subject Up to 1 year after injection No
Secondary Number of participants with visualization of the biliary system for the pre-contrast images If relevant to the subject Up to 1 year after injection No
Secondary Number of participants with visualization of the biliary system for the combined images If relevant to the subject Up to 1 year after injection No
Secondary Number of participants with diagnostic confidence for the pre-contrast images Up to 1 year after injection No
Secondary Number of participants with diagnostic confidence for the combined images Up to 1 year after injection No
See also
  Status Clinical Trial Phase
Recruiting NCT03785171 - Predicative Value of Multimodal MRI in Moyamoya Disease
Not yet recruiting NCT03726788 - Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis Phase 2
Active, not recruiting NCT01956409 - Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis Phase 4
Completed NCT01660841 - Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging Phase 3
Recruiting NCT03635619 - The Application of 3T MRI in Esophageal Cancer
Recruiting NCT03658343 - T2* MRI Analysis for Sarcoma N/A
Recruiting NCT04555642 - Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI
Active, not recruiting NCT03441867 - Neuroimaging Biomarker for Seizures N/A
Recruiting NCT04850001 - Cognitive Decline in Asymptomatic Intracranial Stenosis Patients: A 1-Year Follow-Up Study
Not yet recruiting NCT05816213 - Point-of-care Low-field MRI in Acute Stroke
Active, not recruiting NCT05498623 - MR Fingerprinting for Diagnostic of Prostate Cancer
Recruiting NCT04257747 - Qualitative and Quantitative Evaluation of Vascular Flows of Radial, Ulnar and Interdigital Arterial Trees Under Normal and Pathological Conditions by 3 Tesla MRI N/A
Recruiting NCT04996615 - Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening Breast Cancer in High-risk Women
Recruiting NCT05889117 - Brain Stimulation for Concussion N/A
Completed NCT02540967 - Drug Use Investigation of Gadovist.
Completed NCT05103189 - 4D-flow Cardiac MRI to Assess Pulmonary Arterial Pressure in Pulmonary Hypertension N/A
Completed NCT02567318 - Is the Volume of the Caudate Nuclei Associated With Area of Secondary Hyperalgesia? N/A
Recruiting NCT02834585 - Magnetic Resonance Imaging or Ultrasound in Soft Tissue Tumors (MUSTT) N/A
Active, not recruiting NCT02446665 - Disease Status in Primary Sclerosing Cholangitis by Elastography N/A
Completed NCT01721785 - Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer N/A